Table 4.

Subgroup analysis of individual neuromuscular blocking agents

		Cases receiving neostigmine				Cases not receiving neostigmine
	Neuromuscular blocking agent	Cases receiving NMB	NMB total dose (ED 95 Equivalent)a	Time between last NMB & extubation (minutes)	Total dose of neostigmine (mcg/kg)b	Cases receiving NMB	NMB total dose (ED 95 Equivalent)a	Time between last NMB & extubation (minutes)
		N	Median [IQR]	Median [IQR]	Median [IQR]	N	Median [IQR]	Median [IQR]
No Succinylcholine	Atracurium	2981	3.9 [2.6, 5.9]	67.0 [50.0, 90.0]	33.7 [29.7, 41.7]	906	2.9 [2.1, 4.7]	119.0 [85.0, 174.0]
	Cisatracurium	12,905	5.6 [3.9, 8.3]	73.0 [53.0, 102.0]	36.0 [30.2, 42.4]	2596	4.6 [3.1, 7.1]	136.0 [90.0, 204.0]
	Pancuronium	134	1.3 [0.1, 2.3]	99.5 [62.0, 161.0]	47.2 [35.8, 61.7]	48	0.1 [0.1, 0.1]	210.5 [150.5, 265.0]
	Rocuronium	5602	2.8 [2.2, 4.0]	83.0 [59.0, 117.0]	36.6 [29.8, 41.7]	1510	2.4 [1.8, 3.4]	126.0 [89.0, 174.0]
	Vecuronium	65,708	3.4 [2.4, 4.9]	76.0 [55.0, 108.0]	38.2 [31.5, 42.2]	7343	2.8 [2.0, 4.5]	145.0 [93.0, 233.0]
	Multiple NMBAs	1185	5.9 [4.4, 8.0]	71.0 [52.0, 101.0]	39.0 [32.1, 44.9]	216	6.6 [4.8, 8.6]	92.0 [37.5, 162.5]
Succinylcholine	Atracurium	1407	3.4 [2.2, 5.4]	60.0 [46.0, 84.0]	31.8 [28.2, 39.0]	439	2.5 [1.5, 4.4]	95.0 [65.0, 141.0]
	Cisatracurium	4591	4.8 [2.9, 7.6]	65.0 [49.0, 88.0]	32.7 [28.8, 40.0]	864	4.1 [2.2, 7.5]	106.0 [68.0, 153.0]
	Pancuronium	63	2.1 [1.2, 2.6]	96.0 [74.0, 140.0]	37.0 [31.6, 48.0]	1025	0.1 [0.1, 0.1]	101.5 [60.0, 181.5]
	Rocuronium	674	2.1 [1.3, 3.0]	62.0 [42.0, 87.0]	32.1 [26.1, 39.4]	232	1.0 [0.3, 2.0]	81.0 [53.0, 129.0]
	Vecuronium	21,514	3.0 [1.9, 4.7]	67.0 [49.0, 93.0]	36.7 [30.0, 41.3]	3026	2.6 [1.3, 4.8]	115.0 [67.0, 195.0]
	Multiple NMBAs	359	3.6 [2.2, 5.6]	65.0 [46.0, 94.0]	35.1 [30.0, 41.3]	305	3.0 [1.5, 6.3]	82.0 [41.0, 154.0]

^aOnly among patients with IBW between 40 and 250 kg

^bOnly among patients with TBW between 40 and 250 kg